Q BioMed Inc

Change company Symbol lookup

Select an option...

QBIO Q BioMed Inc

VORB Virgin Orbit Holdings Inc

LBTYA Liberty Global PLC

TDOC Teladoc Health Inc

BRSH Bruush Oral Care Inc

RNA Avidity Biosciences Inc

ATAI ATAI Life Sciences NV

VTI Vanguard Total Stock Market Index Fund ETF Shares

AMPS Altus Power Inc

BPTS Biophytis SA

Go

Q BioMed, Inc. is a biomedical acceleration and development company. The Company focuses on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed acquires assets across healthcare related products, companies and sectors. It has portfolio of five therapeutic products, including Strontium-89 and MetastronTM for metastatic bone cancer pain and three development stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder; Uttroside-B for liver cancer, and MAN 01 for glaucoma. Its MAN platform has therapeutics in development in various indications, including vascular and infectious diseases. It holds license for a generic drug, Strontium Chloride (SR89). SR89 is a radiopharmaceutical agent and indicated for the treatment of bone cancer. The infectious diseases that it can treat includes influenza, COVID-19, Ebola and others. The Company's subsidiaries include Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG.